US 11168144
Activatable anti-PDL1 antibodies, and methods of use thereof
granted A61KA61K2039/505A61K2039/507
Quick answer
US patent 11168144 (Activatable anti-PDL1 antibodies, and methods of use thereof) held by CytomX Therapeutics, Inc. expires Mon Nov 04 2041 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- CytomX Therapeutics, Inc.
- Grant date
- Tue Nov 09 2021 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Nov 04 2041 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 39
- CPC classes
- A61K, A61K2039/505, A61K2039/507, A61K2039/545, A61K2300/00